The ALB Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the ALB gene, eliminating albumin expression. This loss-of-function model, established in the HeLa cervical carcinoma background, enables exploration of albumin-dependent functions outside the liver.
HeLa cells, derived from human cervical adenocarcinoma, are highly proliferative, aneuploid, and contain HPV-18 sequences, making them an immortalized and well-characterized platform for genetic manipulation. Their widespread use in cell biology ensures compatibility with diverse experimental assays.
The ALB gene encodes serum albumin, a multifunctional protein secreted mainly by the liver that maintains colloidal osmotic pressure, acts as an antioxidant, and serves as a carrier for a vast array of endogenous and exogenous ligands??including long-chain fatty acids, thyroxine, steroid hormones, bilirubin, heme, metal ions, and numerous pharmaceutical agents. In hepatocytes, albumin synthesis is transcriptionally activated through binding sites for HNF1, C/EBP, and the glucocorticoid receptor, with IL-6 providing cytokine-mediated induction. Extracellularly, albumin engages the gp60 receptor (albondin) on endothelial and epithelial surfaces, triggering caveolin-1 phosphorylation and Src kinase activation to orchestrate caveolae-mediated transcytosis. The albumin?Cgp60?Ccaveolin-1?CSrc axis culminates in dynamin-dependent vesicle fission, enabling transport of albumin and its cargo across cellular barriers. Additional albumin-binding partners include megalin and cubilin, which mediate reabsorption in the kidney, and SPARC, which modulates albumin?Ctumor interactions. In the ALB knockout HeLa polyclonal cells, all these receptor?Cligand interactions are abolished, because albumin expression is eliminated. This loss disrupts the entire spectrum of albumin-triggered signaling and trafficking pathways, providing a defined reductionist model.
Deploying HeLa cells as the host capitalizes on their exceptionally well-characterized proteome, rapid proliferation, and compatibility with high-throughput transfection and imaging. Since HeLa cells derive from a cervical carcinoma, this knockout model allows investigation of albumin-mediated processes in a cancer context without confounding hepatic functions. Researchers can examine how albumin influences drug sensitivity, nanoparticle internalization, and transendothelial migration. The polyclonal nature of the population mirrors natural heterogeneity, making it suitable for broad pathway interrogation and initial screening studies.
Routine experimental approaches include western blotting and RT-qPCR for verifying ALB disruption, ELISA and immunofluorescence to assess protein loss, and functional assays such as albumin uptake using fluorescent conjugates, transwell transcytosis measurements, and cell viability tests with albumin-bound chemotherapeutics. Ligand-binding studies can further dissect how specific cargoes rely on albumin for cellular entry. The knockout cells also provide an ideal negative control for hepatic albumin research and for studies involving gp60, caveolin-1, or SPARC. For more information, please contact Ascent Research.
